WO2009140383A3 - Aptamers that bind to p-selectin and their use as coagulation, thrombotic, inflammatory, and metastatic disease therapeutics - Google Patents

Aptamers that bind to p-selectin and their use as coagulation, thrombotic, inflammatory, and metastatic disease therapeutics Download PDF

Info

Publication number
WO2009140383A3
WO2009140383A3 PCT/US2009/043787 US2009043787W WO2009140383A3 WO 2009140383 A3 WO2009140383 A3 WO 2009140383A3 US 2009043787 W US2009043787 W US 2009043787W WO 2009140383 A3 WO2009140383 A3 WO 2009140383A3
Authority
WO
WIPO (PCT)
Prior art keywords
selectin
aptamers
bind
thrombotic
coagulation
Prior art date
Application number
PCT/US2009/043787
Other languages
French (fr)
Other versions
WO2009140383A2 (en
Inventor
Robert Schaub
Jeffrey Kurz
Original Assignee
Archemix Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archemix Corp. filed Critical Archemix Corp.
Publication of WO2009140383A2 publication Critical patent/WO2009140383A2/en
Publication of WO2009140383A3 publication Critical patent/WO2009140383A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Materials and methods are provided to prepare targeting nucleic acids and more particularly to aptamers that bind to P-selectin, which are useful as therapeutics in and diagnostics of coagulation/thrombotic, inflammatory, metastatic and/or other pathologies, diseases or disorders in which P-selectin has been implicated. In addition, the aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. Materials and methods for the administration of aptamers that bind to P-selectin are also provided.
PCT/US2009/043787 2008-05-13 2009-05-13 Aptamers that bind to p-selectin and their use as coagulation, thrombotic, inflammatory, and metastatic disease therapeutics WO2009140383A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US12762908P 2008-05-13 2008-05-13
US61/127,629 2008-05-13
US13218208P 2008-06-16 2008-06-16
US61/132,182 2008-06-16
US12264208P 2008-12-15 2008-12-15
US61/122,642 2008-12-15
US16722509P 2009-04-07 2009-04-07
US61/167,225 2009-04-07

Publications (2)

Publication Number Publication Date
WO2009140383A2 WO2009140383A2 (en) 2009-11-19
WO2009140383A3 true WO2009140383A3 (en) 2010-01-07

Family

ID=41319314

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/043787 WO2009140383A2 (en) 2008-05-13 2009-05-13 Aptamers that bind to p-selectin and their use as coagulation, thrombotic, inflammatory, and metastatic disease therapeutics

Country Status (1)

Country Link
WO (1) WO2009140383A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2390425T3 (en) 2000-12-22 2012-11-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive targeting molecules (RGM) and their modulators
EP1928905B1 (en) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
JP5951498B2 (en) 2009-12-08 2016-07-13 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Monoclonal antibody against RGMA protein for use in the treatment of retinal nerve fiber layer degeneration
PE20142168A1 (en) 2012-01-27 2015-01-17 AbbVie Deutschland GmbH and Co KG COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH THE DEGENERATION OF NEURITES
DE102013112915A1 (en) * 2013-11-22 2015-05-28 Universitätsklinikum Hamburg-Eppendorf (UKE) DNA aptamers that specifically bind E and P selectins
EP3758715A4 (en) 2018-03-02 2021-12-15 Peter Gillies A method of modulating cell proliferation
CN111803618B (en) * 2020-06-03 2023-05-05 桂林医学院附属医院 Application of GPRP acetate in preparation of medicines for treating ulcerative colitis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072234A1 (en) * 1990-06-11 2004-04-15 Parma David H. High affinity nucleic acid ligands to lectins
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072234A1 (en) * 1990-06-11 2004-04-15 Parma David H. High affinity nucleic acid ligands to lectins
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same

Also Published As

Publication number Publication date
WO2009140383A2 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
WO2009140383A3 (en) Aptamers that bind to p-selectin and their use as coagulation, thrombotic, inflammatory, and metastatic disease therapeutics
EP2467167A4 (en) Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
MX2012011771A (en) Aptamers to î²-ngf and their use in treating î²-ngf mediated diseases and disorders.
WO2010017196A3 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2012174487A8 (en) Bromodomain inhibitors and uses thereof
WO2012151512A3 (en) Bromodomain inhibitors and uses thereof
WO2012104655A3 (en) Compostions and methods for treating chronic inflammation and inflammatory diseases
WO2012075383A3 (en) Bromodomain inhibitors and uses thereof
WO2014144280A3 (en) Dual specific binding proteins directed against il-1 beta and il-17
WO2013151736A3 (en) In vivo production of proteins
WO2010127294A3 (en) Dual variable domain immunoglobulins and uses thereof
WO2010151640A3 (en) Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
WO2011039368A3 (en) Dll4-binding molecules
WO2007025049A3 (en) Aptamers that bind thrombin with high affinity
WO2008076392A3 (en) Compounds useful as protein kinase inhibitors
PT2356109T (en) Compositions and methods for treating alcohol use disorders, pain and other diseases
WO2010009478A3 (en) Compositions and methods for treating disorders associated with overweight animals
WO2012135671A3 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2009061800A3 (en) Methods and compositions for diagnostic use in cancer patients
WO2008127654A3 (en) Methods and compositions for intra-articular coagulation proteins
WO2009040413A3 (en) An ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
WO2006087393A3 (en) Structural analogues of avenanthramides, their use in compositions useful in the treatment of dermatological disorders
WO2011011631A3 (en) Nucleic acid delivery vehicles
WO2009102438A3 (en) Aptamer inhibitors of osteopontin and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09747467

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09747467

Country of ref document: EP

Kind code of ref document: A2